Novavax (NVAX) Stock Price Today—Real Time Charts and Quotes

Q: What are the 52-week high and low prices for Novavax (NVAX)?

NVAX has a 52-week high of $0 and a 52-week low of $0, with the current price at $0.

Q: What is the price-to-earnings (P/E) ratio of Novavax (NVAX)? What does it indicate?

The current P/E ratio (TTM) of NVAX is 2.47234743426103, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of Novavax (NVAX)?

Novavax (NVAX) currently has a market cap of approximately $1.31B.

Q: What is the most recent quarterly earnings per share (EPS) for Novavax (NVAX)?

Novavax (NVAX)'s diluted earnings per share (Diluted EPS) is 2.7180645838349045. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Novavax (NVAX) now?

As of now, NVAX is trading at $0, with a P/E ratio of 2.47234743426103 and a diluted EPS of 2.7180645838349045. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Novavax's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Novavax (NVAX)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Novavax (NVAX) stock?

You can buy Novavax (NVAX) through Gate. Sign up for a Gate account and complete identity verification, then go to the Novavax trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

+$0(0,00%)

Nessun dato

*Data last updated: 2026-04-28 20:38 (UTC+8)

As of 2026-04-28 20:38, Novavax (NVAX) is priced at $0, with a total market cap of $1,31B, a P/E ratio of 2,47, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 2,58M. Over the past 52 weeks, NVAX has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

NVAX Key Stats

Yesterday's Close$8

Market Cap$1,31B

Volume2,58M

P/E Ratio2,47

Dividend Yield (TTM)0,00%

Diluted EPS (TTM)2,71

Net Income (FY)$440,30M

Revenue (FY)$1,12B

Earnings Date2026-05-14

EPS Estimate0,25

Revenue Estimate$78,32M

Shares Outstanding159,96M

Beta (1Y)2.648

About NVAX

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

SectorHealthcare

IndustryBiotechnology

CEOJohn Charles Jacobs

HeadquartersGaithersburg,MD,US

Official Websitehttps://www.novavax.com

Employees (FY)749,00

Average Revenue (1Y)$1,49M

Net Income per Employee$587,85K

Novavax (NVAX) FAQ

What's the stock price of Novavax (NVAX) today?

Novavax (NVAX) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Novavax (NVAX)?

What is the price-to-earnings (P/E) ratio of Novavax (NVAX)? What does it indicate?

What is the market cap of Novavax (NVAX)?

What is the most recent quarterly earnings per share (EPS) for Novavax (NVAX)?

Should you buy or sell Novavax (NVAX) now?

What factors can affect the stock price of Novavax (NVAX)?

How to buy Novavax (NVAX) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.